Celcuity https://validator.w3.org/feed/docs/rss2.html Block Pam. Unlock Tomorrow Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”) Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 Celcuity Appoints Charles Romp to its Board of Directors Celcuity To Participate in Upcoming Investor Conferences Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Senior Manager, Commercial Finance and Accounting Senior Medical Director Senior Quality Assurance Auditor Senior or Principal Scientist, Formulation and Process Development Senior Manager, Clinical Data Management Director, Strategic Accounts QMS Training Manager Senior Manager/Associate Director, Statistical Programming Facilities Manager Senior Manager, Accounting Oncology Sales Specialist Director, Safety Science Associate Scientist, Cell Signaling and Assay Development Director, Medical Science Liaison, Carolinas Director, Medical Science Liaison, North Central (Chicago, Illinois) Director or Senior Director, API Development Associate Director, Clinical Scientist Associate Director, Field Operations Associate Director, R&D Laboratory Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call Celcuity to Participate in the Cowen 42nd Annual Health Care Conference Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call